Literature DB >> 33964375

GALNT2/14 overexpression correlate with prognosis and methylation: potential therapeutic targets for lung adenocarcinoma.

Yilin Yu1, Zhiping Wang1, Qunhao Zheng1, Jiancheng Li2.   

Abstract

OBJECTIVE: GALNT2/14 are members of the glycosyltransferase protein family, which initiate mucin-type O-glycosylation of peptides in the Golgi apparatus. However, the correlation between GALNT2/14 and disease prognosis and methylation in lung adenocarcinoma (LUAD) remains unclear. Thus, we sought to identify their potential values in LUAD.
METHODS: GALNT2/14 expressions were analyzed using publicly-available datasets. The association between GALNT2/14 and disease prognosis was evaluated. In addition, gene set enrichment analysis (GSEA) and single sample GSEA (ssGSEA) were used to explore the potential biological functions of GALNT2/14. The correlation between the copy number variations and methylation level of GALNT2/14 and their mRNA expressions was analyzed via cBioPortal. Finally, we explored the prognostic value of the GALNT2/14 methylation levels by MethSurv in LUAD.
RESULTS: GALNT2/14 were highly expressed in LUAD tumor tissue than normal tissue (P < 0.001). Multivariate analysis showed that high GALNT2/14 expressions were both an independent prognostic factor. GSEA found that GALNT2/14 expressions were associated with the methylation, gene silencing, and cell division, whereas immune analysis showed that GALNT2/14 expressions positively correlated with the expression level of PD-L1. Finally, the methylation levels of GALNT2/14 negatively correlated with the GALNT2/14 expressions (R = -0.26 and -0.36, P < 0.001, respectively), and patients with GALNT2/14 hypomethylation had worse overall survival than patients with high methylation (P < 0.05).
CONCLUSIONS: This study demonstrated that the overexpression of GALNT2/14 in LUAD can serve as biomarkers for poor prognosis. The biological functions of GALNT2/14 are potentially related to methylation, gene silencing, tumorigenesis, and cell division. These findings help elucidate the role of GALNT2/14 in tumorigenesis and provide additional insight for therapy and prognosis of LUAD.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  GALNT2/14; Immune infiltration; Lung adenocarcinoma; Methylation; Prognosis; TCGA

Year:  2021        PMID: 33964375     DOI: 10.1016/j.gene.2021.145689

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  3 in total

Review 1.  Glycosyltransferases in Cancer: Prognostic Biomarkers of Survival in Patient Cohorts and Impact on Malignancy in Experimental Models.

Authors:  Michela Pucci; Martina Duca; Nadia Malagolini; Fabio Dall'Olio
Journal:  Cancers (Basel)       Date:  2022-04-24       Impact factor: 6.575

2.  PLAUR as a Potential Biomarker Associated with Immune Infiltration in Bladder Urothelial Carcinoma.

Authors:  Mulin Liu; Siyi Chen; Aihui Zhang; Qin Zheng; Juan Fu
Journal:  J Inflamm Res       Date:  2021-09-15

3.  The O-glycosylating enzyme GALNT2 acts as an oncogenic driver in non-small cell lung cancer.

Authors:  Qing Hu; Tian Tian; Yahui Leng; Yuanhui Tang; Shuang Chen; Yueyao Lv; Jingyin Liang; Yanni Liu; Tianhui Liu; Li Shen; Xiaoxia Dong
Journal:  Cell Mol Biol Lett       Date:  2022-09-04       Impact factor: 8.702

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.